Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Congress Already Impacting Industry Drug Pricing Abuses, Valeant Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Valeant investor, board member Ackman, outgoing CEO Pearson suggest congressional hearings have made a significant impression on biopharma industry.


Related Content

Valeant Gives Siliq Competitive Price In Crowded Psoriasis Market
Just Trust Me: Most Firms Unwilling To Publicly Pledge Pricing Restraint
Senate Committee Closes Books On 2016 Pricing Investigation; PBMs In Hot Seat Next?
At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts